| Title |
Osteoporosis: Treat-to-Target
|
|---|---|
| Published in |
Current Osteoporosis Reports, February 2017
|
| DOI | 10.1007/s11914-017-0350-7 |
| Pubmed ID | |
| Authors |
E. Michael Lewiecki |
| Abstract |
Treat-to-target (goal-directed therapy) has been proposed as a strategy to assist clinicians in selecting the most appropriate initial treatment for osteoporosis and guiding subsequent decisions to continue, change, or stop treatment. This is a review of the current medical evidence regarding treatment targets and potential clinical applications in managing patients with osteoporosis. Analyses of randomized placebo-controlled trials of approved agents to treat osteoporosis have generally shown that larger increases in bone mineral density are associated with greater reduction in fracture risk. Achievement of T-scores > -2.5 to -2.0 with treatment appears to provide little additional fracture protection. The paradigm of treat-to-target is aimed at enhancing and individualizing the care of patients with osteoporosis. Based on the best available data, the most promising target is T-score > -2.5. More data are needed to validate the clinical utility of treat-to-target for osteoporosis. |
X Demographics
The data shown below were collected from the profiles of 2 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Netherlands | 1 | 50% |
| Unknown | 1 | 50% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 1 | 50% |
| Scientists | 1 | 50% |
Mendeley readers
The data shown below were compiled from readership statistics for 28 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 28 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Master | 5 | 18% |
| Researcher | 4 | 14% |
| Student > Ph. D. Student | 4 | 14% |
| Student > Bachelor | 3 | 11% |
| Student > Doctoral Student | 2 | 7% |
| Other | 6 | 21% |
| Unknown | 4 | 14% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 14 | 50% |
| Pharmacology, Toxicology and Pharmaceutical Science | 4 | 14% |
| Biochemistry, Genetics and Molecular Biology | 4 | 14% |
| Engineering | 2 | 7% |
| Unknown | 4 | 14% |
Attention Score in Context
This research output has an Altmetric Attention Score of 1. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 06 September 2021.
All research outputs
#17,881,664
of 22,958,253 outputs
Outputs from Current Osteoporosis Reports
#360
of 548 outputs
Outputs of similar age
#224,850
of 311,651 outputs
Outputs of similar age from Current Osteoporosis Reports
#9
of 12 outputs
Altmetric has tracked 22,958,253 research outputs across all sources so far. This one is in the 19th percentile – i.e., 19% of other outputs scored the same or lower than it.
So far Altmetric has tracked 548 research outputs from this source. They receive a mean Attention Score of 4.8. This one is in the 26th percentile – i.e., 26% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 311,651 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 23rd percentile – i.e., 23% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 12 others from the same source and published within six weeks on either side of this one. This one is in the 8th percentile – i.e., 8% of its contemporaries scored the same or lower than it.